EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

What’s in a word? Defining “gene therapy medicines”

Maren von Fritschen, Ewa Janosz, Constanze Blume, Ulrike Jägle, Karen Keating, Christian K Schneider

Molecular Therapy - Methods & Clinical Development · 2024-12 · 32 (4) · 101348

DOI: 10.1016/j.omtm.2024.101348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy - Methods & Clinical Development, 2024-12. Verfasst von Maren von Fritschen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Moderna Netherlands, Claude Debussylaan 7, 1082 MC Amsterdam Zuid, the Netherlands. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gene therapy medicinal products (GTMPs) have emerged as a transformative class of medicines. Defining what a certain class of medicines encompasses, and what it does not, is key, with ample implications and consequential regulatory requirements. In April 2023, the European Commission proposed new pharmaceutical legislation safeguarding the public health within the European Union with a new, broader definition of GTMP, including genome editing medicines and nucleic acids of either source, regulating, replacing, or adding a genetic sequence that mediates its effect by transcription or translation. This definition is all-encompassing for any "genetic" intervention and is agnostic to mechanism of action, duration of action, location of action, and associated risk. Here, we take this as a paradigm to discuss how terminology and definitions are more than just words and can have meaningful regulatory, scientific, and public health implications.

Autor:innen und Institutionen

  • Moderna Netherlands, Claude Debussylaan 7, 1082 MC Amsterdam Zuid, the Netherlands.
  • Cencora PharmaLex, Basler Strasse 7, 61352 Bad Homburg, Germany.
  • BioNTech SE, An der Goldgrube 12, 55131 Mainz, Germany.
  • CureVac SE, Leipziger Strasse 35, 65191 Wiesbaden, Germany.
  • TWINCORE Zentrum für Experimentelle und Klinische Infektionsforschung GmbH, Feodor-Lynen-Strasse 7, 30625 Hannover, Germany.

Zitieren

APA

von Fritschen, M., Janosz, E., Blume, C., Jägle, U., Keating, K., & Schneider, C. K. (2024). What’s in a word? Defining “gene therapy medicines”. Molecular Therapy - Methods & Clinical Development, 32(4), 101348. https://doi.org/10.1016/j.omtm.2024.101348

Vancouver

von Fritschen M, Janosz E, Blume C, Jägle U, Keating K, Schneider CK. What’s in a word? Defining “gene therapy medicines”. Molecular Therapy - Methods & Clinical Development. 2024;32(4):101348. doi:10.1016/j.omtm.2024.101348

BibTeX
@article{vonFritschen2024,
  author = {von Fritschen, Maren and Janosz, Ewa and Blume, Constanze and Jägle, Ulrike and Keating, Karen and Schneider, Christian K},
  title = {What’s in a word? Defining “gene therapy medicines”},
  journal = {Molecular Therapy - Methods & Clinical Development},
  year = {2024},
  volume = {32},
  number = {4},
  pages = {101348},
  doi = {10.1016/j.omtm.2024.101348}
}
Kostenlos starten →